Cargando…

Hepatic microbiome in healthy lean and obese humans

BACKGROUND & AIMS: Dysbiosis of the gut microbiota in response to an energy-rich Western diet and the potential leak of bacteria and/or bacterial products from the intestine to the liver is perceived as a potential risk factor for the development of non-alcoholic fatty liver disease (NAFLD). We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Suppli, Malte Palm, Bagger, Jonatan Ising, Lelouvier, Benjamin, Broha, Amandine, Demant, Mia, Kønig, Merete Juhl, Strandberg, Charlotte, Lund, Asger, Vilsbøll, Tina, Knop, Filip Krag
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8207208/ https://www.ncbi.nlm.nih.gov/pubmed/34169247 http://dx.doi.org/10.1016/j.jhepr.2021.100299

Ejemplares similares

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat
por: Mathiesen, David S., et al.
Publicado: (2021)

The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review
por: Mathiesen, David S., et al.
Publicado: (2019)

Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial
por: Johansen, Nicklas Järvelä, et al.
Publicado: (2018)

A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes
por: Andersen, Andreas, et al.
Publicado: (2021)

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment
por: Subramanian, Vijaya, et al.
Publicado: (2022)

Mechanisms of the Incretin Effect in Subjects with Normal Glucose Tolerance and Patients with Type 2 Diabetes
por: Mari, Andrea, et al.
Publicado: (2013)

Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report
por: Knop, Filip K, et al.
Publicado: (2014)

How glucagon-like peptide 1 receptor agonists work
por: Andreasen, Christine Rode, et al.
Publicado: (2021)

On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes
por: Sonne, David P, et al.
Publicado: (2014)

The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials
por: Storgaard, Heidi, et al.
Publicado: (2014)

Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes
por: Christensen, Mikkel B, et al.
Publicado: (2020)

Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption
por: Kårhus, Martin Lund, et al.
Publicado: (2021)

No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect
por: Mathiesen, David S, et al.
Publicado: (2020)

Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial
por: Sidelmann Christensen, Alexander, et al.
Publicado: (2018)

Response to Letter to the Editor from McKee and McGill: “Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring”
por: Juel, Caroline T B, et al.
Publicado: (2021)

The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition
por: Hædersdal, Sofie, et al.
Publicado: (2020)

Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials
por: Hansen, Morten, et al.
Publicado: (2012)

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes
por: Fotheringham, Amelia K., et al.
Publicado: (2020)

The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial
por: Larsen, Emil List, et al.
Publicado: (2017)

The effect of curcumin on hepatic fat content in individuals with obesity
por: Hellmann, Pernille H., et al.
Publicado: (2022)

No effect of the turmeric root phenol curcumin on prednisolone-induced glucometabolic perturbations in men with overweight or obesity
por: Hellmann, Pernille H, et al.
Publicado: (2023)

A 25-Year-Old Woman with Type 2 Diabetes and Liver Disease
por: Junker, Anders Ellekær, et al.
Publicado: (2014)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
por: Gluud, Lise L, et al.
Publicado: (2014)

Effects of glucagon‐like peptide‐1 receptor agonists on cardiovascular risk factors: A narrative review of head‐to‐head comparisons
por: Dalsgaard, Niels B., et al.
Publicado: (2017)

Different Effects of Once-weekly and Once-daily Administered GLP-1RA Semaglutide and Liraglutide on Bile Acid Diarrhea
por: Kårhus, Martin Lund, et al.
Publicado: (2022)

Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study
por: Andersen, Andreas, et al.
Publicado: (2021)

Acute changes in plasma glucose increases left ventricular systolic function in insulin‐treated patients with type 2 diabetes and controls
por: Andersen, Andreas, et al.
Publicado: (2022)

Hypoglycaemia and cardiac arrhythmias in diabetes
por: Andersen, Andreas, et al.
Publicado: (2020)

One Year’s Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial
por: Vedtofte, Louise, et al.
Publicado: (2020)

Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls
por: Andersen, Andreas, et al.
Publicado: (2021)

Glucose-Dependent Insulinotropic Polypeptide: A Bifunctional Glucose-Dependent Regulator of Glucagon and Insulin Secretion in Humans
por: Christensen, Mikkel, et al.
Publicado: (2011)

Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
por: Holst, Jens J., et al.
Publicado: (2011)

Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies
por: Rohde, Ulrich, et al.
Publicado: (2013)

Mechanism‐Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake
por: Guiastrennec, B, et al.
Publicado: (2016)

Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials
por: Vilsbøll, Tina, et al.
Publicado: (2012)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Why diversity among participants in clinical studies is not always preferable: the case for small, exploratory studies
por: Ellegaard, Anne-Marie, et al.
Publicado: (2023)

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course
por: Mikkelsen, Kristian H., et al.
Publicado: (2018)

Model‐Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans
por: Guiastrennec, Benjamin, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_e58gbgkp9envdlq24ad0okkgoq